Earnings Releases·Oct 29, 2026, 4:08 PM ET

Supernus Pharmaceuticals, Inc. — Third Quarter 2026 Earnings Summary

Total revenues rose 18% year-over-year to $226.8 million in Q3 2026, driven by a 107% surge in ZURZUVAE collaboration revenue to $41.7 million, while operating earnings turned positive at $21.2 million compared to a $60.2 million loss in the prior year period.
Full-year 2026 guidance was raised across all metrics: total revenue to $875–$900 million, GAAP operating loss to $(5)–$(40) million, and non-GAAP adjusted operating earnings to $160–$180 million, contingent on the company remaining a stand-alone entity.
The company is proceeding with its all-stock merger with Indivior, approved by shareholders and expected to close on November 2, 2026, creating a combined entity named Supernus, Inc. with projected $125 million in annual cost synergies.
Commercial momentum was evident with combined growth product revenues up 29% year-over-year to $192.2 million, led by ONAPGO sales increasing 151% to $17.1 million and Qelbree sales rising 12% to $90.8 million.